+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the XEN63 glaucoma gel stent implanted using two different surgical methods ab interno inside the eye and ab externo outside the eye. This study focuses on patients with glaucoma who have not responded well to medical treatments or conventional surgeries. The trial aims to compare outcomes such as adverse events and intraocular pressure control over 12 months. Participants will be randomly assigned to receive the XEN63 gel stent implanted via either the ab interno or ab externo approach on Day 1. About 130 adults aged 45 years or older with glaucoma will join this study. After implantation, participants will be followed for up to 12 months with regular hospital or clinic visits to monitor safety and effectiveness. During the study, participants will undergo medical assessments and eye exams to measure intraocular pressure and check for any adverse events. The main outcomes include the percentage of participants achieving a 20% or greater reduction in intraocular pressure on the same or fewer medications after 12 months. Secondary measures include changes in daily intraocular pressure and medication use. The study will be completed by November 2028.

Age: 45Years +All GendersPhase 3
29 locations
E

Actively Recruiting

Researchers are evaluating a preservative-free formulation of Bimatoprost ophthalmic solution 0.01% YSBP compared to Lumigan49 bimatoprost ophthalmic solution 0.01% in adults with primary open-angle glaucoma POAG or ocular hypertension OH. The purpose is to establish whether YSBP is not less effective than Lumigan49 in lowering eye pressure in these patients. Participants will be randomly assigned to receive either YSBP or Lumigan49 eye drops. Both treatments contain bimatoprost 0.01%, and the study is designed as a double-blind, active-controlled, parallel-group trial. The treatment period lasts 12 weeks, during which participants will use the assigned eye drops as directed. During the study, participants will undergo regular eye pressure measurements, including the primary outcome of intra-ocular pressure at Week 12. Visual acuity and safety assessments will also be performed. Women of childbearing potential must use effective contraception. The study includes screening, a washout period for prior eye medications, treatment visits, and safety monitoring through the completion date in late 2027.

Age: 18Years +All GendersPhase 3
22 locations
A

Actively Recruiting

Researchers are evaluating the bioequivalence of two eye drop treatments, Bimatoprost 0.01% ophthalmic solution by Amneal EU and LUMIGAN4 bimatoprost ophthalmic solution 0.01% by Allergan, in adults with chronic open-angle glaucoma or ocular hypertension affecting both eyes. This randomized, double-blind, parallel-group study aims to compare these treatments by measuring their effects on intraocular pressure IOP as the primary clinical endpoint. Participants will be randomly assigned to receive either the test or reference bimatoprost eye drops, instilling one drop in both eyes every evening around 1000 pm for 42 days. The study includes multiple doses over this period, with evaluations occurring at baseline, two weeks, and six weeks. The test and reference products are both ophthalmic solutions containing the same concentration of bimatoprost. Throughout the study, participants will have clinical assessments to monitor safety and efficacy, including IOP measurements at specific times 0000, 0400, and 0800 hours on days 14 and 42. Safety monitoring for adverse events will continue during the six-week treatment period. The main outcome is the mean difference in IOP between the treatment groups, helping to determine if the test product is equivalent to the reference product in controlling eye pressure.

Age: 18Years +All GendersPhase 3
9 locations
E

Actively Recruiting

Distal symmetric polyneuropathy, also called diabetic neuropathy, is a common nerve complication of diabetes that affects the longest nerve fibers, especially in the toes and feet. It causes sensory loss, pain, and increases the risk of foot ulcers and amputations, which lowers quality of life. This condition is usually not reversible, and current management focuses on slowing its progression and preventing complications. The study aims to evaluate the use of semiconductor embedded therapeutic socks in managing this condition over a 12-week rehabilitation period. The study compares the effects of semiconductor embedded therapeutic socks, which emit mid and far infrared waves and negative ions to improve blood flow and reduce inflammation, against placebo socks that do not contain this fabric. Participants will wear these socks during the 12-week treatment phase. The socks technology is believed to activate biological pathways that reduce pain and inflammation locally, unlike systemic treatments. The study will collect outcome measures at standard intervals to assess the socks impact on diabetic neuropathy symptoms and function. Participants will be assessed before and after treatment using specific questionnaires and physical exams to measure function, pain, symptom severity, and foot tissue oxygenation. Compliance with sock use will be monitored weekly. The primary outcome is improved patient function measured by standardized scales over 12 weeks. Secondary outcomes include pain reduction, symptom improvement, and better blood oxygen levels in the feet. The study is randomized, double-blind, and will last at least 12 weeks for each participant.

Age: 18Years - 79YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Healthy Volunteer

This research aims to compare the safety and effectiveness of two types of multifocal contact lenses, ACUVUE4 OASYS MAX 1-Day Multifocal and DAILIES4 AquaComfort Plus4 Multifocal. The study is designed as a randomized, single-masked clinical trial with two parallel groups to evaluate visual acuity and ocular safety in adults aged 40 to 70 years. Participants will be monitored for both near and distance vision performance as well as any lens-related eye events. Participants will be randomly assigned to wear either the Senofilcon A lens ACUVUE4 OASYS MAX 1-Day Multifocal or the Nelfilcon A lens DAILIES4 AquaComfort Plus4 Multifocal for the duration of the study. The study consists of four visits where the lenses performance is assessed at one week and one month after initial fitting. Both lenses are soft multifocal contact lenses designed to correct presbyopia and improve visual acuity at various distances. During the study, participants will undergo evaluations of binocular visual acuity at distance, intermediate, and near ranges, along with monitoring for ocular adverse events and slit lamp findings. The primary outcomes measured include visual acuity at one week and the incidence of lens-related eye issues up to one month. This study requires participants to attend four visits over the course of the study period, which lasts approximately one month after lens fitting.

Age: 40Years - 70YearsAll GendersPhase Not Applicable
11 locations
T

Actively Recruiting

This research aims to evaluate the safety and performance of the Enhanced Lithotripsy System ELS for treating urinary stones in adults. The study focuses on patients aged 21 or older who have a single urinary stone in the ureter. The purpose is to assess how well the ELS can break stones into small fragments that can pass more easily, potentially reducing discomfort. Participants will receive the ELS procedure, which uses low pressure ultrasound combined with microbubbles to pit and fragment the urinary stones. All participants undergo this experimental procedure, and no placebo or comparison group is involved. The study includes follow-up evaluations at 30 days and, if necessary, at 60 days to check for remaining stone fragments via CT scans. During the study, participants will be monitored for stone presence using CT imaging and assessed for changes in pain levels, quality of life, and return to normal daily activities and work. Safety and effectiveness will be evaluated up to 30 days after treatment, with an additional assessment at 60 days if stones remain. The total study duration extends from the procedure through these follow-up periods.

Age: 21Years +All GendersPhase Not Applicable
20 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the fully closed loop Omnipod M System in adults with type 2 diabetes who use basalbolus or basal-only insulin therapy. This multi-center randomized controlled trial lasts 26 weeks, with key results measured after 15 and 26 weeks. After this period, an extension phase allows the control group to switch to the Omnipod M system while the intervention group continues its use. Participants are divided into two groups one uses the Omnipod M system with a study continuous glucose monitor CGM, while the other continues their usual insulin regimen with the study CGM. The extension phase lasts an additional 26 weeks, during which the control group crosses over to use the Omnipod M system. The study includes regular monitoring of glucose levels and insulin use throughout. During the trial, participants will wear the study CGM and either the Omnipod M system or their standard insulin treatment. Researchers will assess blood sugar control through measures like HbA1c and time spent in target glucose ranges at 15 and 26 weeks. Additional evaluations include glucose variability and diabetes-related distress. Participants are expected to use study devices continuously and attend scheduled visits over the trial and extension periods, with safety and adherence closely monitored.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
27 locations
S

Actively Recruiting

Researchers are studying the safety and early effects of combining AdiaVita, a stem cell and exosome product derived from umbilical cord blood, with glutathione in people aged 3 years and older who have Autism Spectrum Disorder ASD. This randomized, participant-blinded crossover trial compares the combination treatment against glutathione alone, focusing on changes in Autism Treatment Evaluation Checklist ATEC scores. The study will include about 100 participants and follows them for 12 months, including screening, treatment, and safety monitoring phases. The treatment is investigational and not approved by the FDA for autism, with some risks such as infusion reactions and no guaranteed benefits. Participants in the active group receive three monthly intravenous infusions of AdiaVita along with escalating doses of glutathione, plus twice-daily transdermal glutathione sprays at home. The control group receives placebo saline infusions with the same glutathione regimen and spray schedule. After six months, participants in the glutathione-only group who meet safety and stability criteria may cross over to receive AdiaVita treatments. The study includes screening, three months of treatment, a six-month primary endpoint evaluation, and a 12-month safety follow-up. During the study, parents and therapists independently complete ATEC evaluations at various timepoints to assess treatment impact. Participants also undergo physical exams, laboratory tests, and monitoring for adverse events. Safety is overseen by an independent board with observation after infusions and predefined stopping rules. Confidentiality is maintained through coded identifiers and secure data systems. Participation costs 12,000 for the initial schedule, while crossover treatments are provided at no extra cost for eligible participants.

Age: 3Years +All GendersPhase 1
2 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations

1-10 of 13

1